Issue #001 showed what happens when institutions deploy systems without encoding their Purpose into what those systems actually optimise toward. Coutts closed an eligible client's account. NHS trusts deprioritised the patients they existed to serve. The failure was not procedural. It was architectural — and it opened before a single decision was made.
Issue #001 introduced Layer 1 — Purpose. The unwavering mandate. The reason why the institution was founded.
Purpose, however, is not enough by itself. Between Purpose and the execution, there lies an entire layer that virtually every institution invests time and money heavily in. But that doesn't mean they all give it the same level of consideration when asking the one question that really matters.
That layer is Strategy.
A proper Strategy is the way in which Purpose comes to life. But left unchecked, it becomes the first point of departure from Purpose.
The failure mode for Layer 2 is subtle. It's not an explicit choice. An institution doesn't opt out of Purpose but opts into a faster pace, more aggressive competition, better metrics, and a certain market. In each case, there may be sound reasons for it. But cumulatively, it shifts the underlying strategy further and further away from Purpose.
When the shift is noticed, it's already too late. There is no longer a need to ask if the strategy aligns with the mandate; the crisis has arrived.
In both cases in this issue, the board approved the strategy. Nobody asked whether it still served the Purpose the institution was built to protect.
This issue examines what that costs — and what asking the question earlier would have changed.
Credit Suisse was founded in 1856. It remained one of Switzerland's most respected financial institutions for more than a century — conservative in design, client-oriented by necessity, established on a reputation of discretion and stability.
As early as 2015, amid shareholder demand and competition from US bulge-bracket banks, Credit Suisse developed a new strategy: to increase prime brokerage operations, grow revenue from investment banking activities, and cultivate relationships with high-margin yet high-risk clients. It was rational in terms of competition, approved by the Board of Directors, praised by analysts, and utterly sound in theory.
Credit Suisse's Purpose — the mandate it had built its reputation on for over a century — was clear: serve private banking clients with discretion, stability, and long-term continuity. Conservative by design. Not a growth vehicle.
The new growth strategy was never formally aligned with that Purpose.
The new growth strategy attracted clients who would never be served by a conservative private bank. These include Archegos Capital Management and Greensill Capital. Both were incompatible with the very purpose of maintaining stability and protecting clients.
Archegos collapsed in 2021. Credit Suisse was hit for CHF 5.5 billion. Credit Suisse was bought out by UBS in March 2023 under emergency government-brokered terms. One of the oldest names in banking disappeared.
The failure didn't happen through any one decision. It happened because the strategy had replaced the Purpose after eight years of competitive bets.
Following the coronavirus outbreak, NHS England had more than 7 million elective operations pending. In 2022, the NHS introduced the Elective Recovery Programme — a plan aimed at clearing the backlog based on specified time scales, target waiting times, and incentives related to the increase in throughput.
The Elective Recovery Plan was not a strategy of clinical nature but rather a strategy of performance. Its purpose was to ensure increased volumes of activity. The process was incentivized financially irrespective of whether the procedure was the most clinically appropriate use of resources.
Independent reviews across multiple trusts from 2023 onwards found the same pattern: assessments compromised by processing speed; patients classified by waiting status rather than clinical complexity; clinical pathways bypassed to hit targets. Not in one trust. Across the system.
There was no violation of any policy because the strategy was doing precisely what it was meant to do. The Purpose it was ignoring was never formally prioritized over it.
Different sectors. Different scales. Identical structural failure.
In both cases, an institution adopted a strategy that was rational, board-approved, and operationally coherent — without engineering a mechanism to continuously ask whether that strategy was still serving the Purpose the institution was built to protect.
In the Decision Integrity Chain™, that mechanism lives at Layer 2 — Strategy.
At Credit Suisse, the growth strategy was never placed in formal relationship with the bank's Purpose. The board approved the strategy. Risk committees reviewed the risks within the strategy. Nobody asked whether the strategy itself was compatible with what the bank had been built to protect. Over eight years, the strategy moved incrementally further from Purpose. Each move was individually defensible. Collectively, they were catastrophic.
At NHS England, the Elective Recovery Strategy was adopted at system level without a formal mechanism to reconcile performance targets with clinical need. When the two competed, the one with the financial incentive attached won.
This is the L2 failure pattern. Strategy drifts from Purpose not through negligence but through momentum. And because no mechanism formally holds the two in relationship, the drift is invisible until the distance is too great to close without a crisis.
Your institution has a strategy. It was approved at board level. Nobody has asked, since approval, whether it still serves the Purpose that board is accountable for protecting.
The Fiduciary Gap opens at Layer 1 when Purpose is not encoded. It compounds at Layer 2 when Strategy is not reconciled with Purpose. An institution that addressed Layer 1 correctly can still fail at Layer 2 — because Purpose-encoding at design does not automatically produce Strategy-Purpose alignment over time.
Both failures were preventable. Not by better risk management within the strategy. By building the mechanism that asks whether the strategy is still the right one.
At every board review, there would have been one mandatory question: Is this growth strategy still consistent with our Purpose — and can we prove that the risk architecture underpinning it is able to safeguard our Purpose?
That question would have made clear that it is impossible to reconcile the conservative mandate of private banking with a prime brokerage growth strategy at that scale. It doesn't mean the firm could not have grown. It means the board would have had to make a documented determination on which aspects of Purpose were non-negotiable.
Prior to implementing Elective Recovery targets, one question must have been raised: Do the incentive mechanisms associated with this approach provide a scenario where clinical need is intentionally subordinated to performance indicators?
Answering this would demand that the programme undergoes a test of alignment with clinical governance requirements prior to the introduction of financial incentives on throughput figures. A positive answer — and it would have been positive — means one of two things must change: cap the throughput incentive, or incorporate a mechanism that allows clinical need to take precedence.
One document. Required before board approval of any material strategic shift. Two questions answered formally — does this strategy serve our Purpose, and under what conditions could it stop doing so? If the second question has no answer, the strategy is not ready for approval. A strategy that cannot name its own failure conditions has been stress-tested against competitors. Not against Purpose.
Not a strategy review. A reconciliation review. The question is not whether the strategy is working. The question is whether it is still compatible with Purpose. One named individual. Board accountability. Annual cadence. Not a governance checkbox. A living record of whether the institution is still doing what it was built to do.
A documented list of what the institution's Purpose will not permit — regardless of competitive logic. Counterparty types that violate the mandate. Incentive structures the clinical obligation cannot tolerate. Growth rates the risk architecture cannot hold. When the strategy is reviewed, this register is reviewed with it. Any breach requires a formal board decision — documented, attributed, owned.
None of these cost money. None require new technology. All three require a board that has decided its strategy will be held accountable to the Purpose that gives the institution its legitimacy.
That is Decision Engineering™ at Layer 2.
When your current strategy was approved, was it formally tested against your institution's Purpose — and has anyone asked that question again since?
If the answer is no, the Fiduciary Gap is not a risk. It is the current condition of your institution.